Arbutus Biopharma (NASDAQ: ABUS) gains 10.8% early after Sanofi Genzyme ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Momentum Movers Trader Talk

Alnylam Pharmaceuticals (ALNY) PT Raised to $123 at Credit SuisseSeptember 21, 2017 6:26 AM Alnylam Pharmaceuticals (ALNY) PT Raised to $125 at Needham & CompanySeptember 20, 2017 3:20 PM Alnylam Pharmaceuticals (ALNY) PT Raised to $83 at StifelSeptember 20, 2017 1:41 PM Alnylam Pharmaceuticals (ALNY) PT Raised to $117 at Cowen; 'Best-Case Scenario'September 20, 2017 12:36 PM Arbutus Biopharma (ABUS) and Alnylam Pharmaceuticals, Inc. (ALNY) Reports Positive Phase 3 Results for LNP-Enabled Patisiran ProgramSeptember 20, 2017 12:25 PM Alnylam Pharmaceuticals (ALNY) PT Raised to $116 at Piper JaffraySeptember 20, 2017 11:39 AM Alnylam Pharma (ALNY) Adds to Gains; Shares up 40%September 20, 2017 10:23 AM Royalty Stream to Arbutus Biopharma (ABUS) from Alnylam (ALNY) 'Could be Significant' - WedbushSeptember 20, 2017 10:19 AM